Merck: Undervalued Pharma Stock With Defensive Approach And Compelling Dividend Yield
Summary
Merck trades at 9.09x forward earnings, far below its 23.55x historical multiple and peers, while maintaining strong pro...
Merck trades at 9.09x forward earnings, far below its 23.55x historical multiple and peers, while maintaining strong profitability and a 3.99% dividend yield. Blockbuster drug Keytruda, along with oncology pipeline and R&D focus, supports long-term growth despite near-term Gardasil sales decline. Heavy reliance on Keytruda, integration of new drugs, Gardasil sales volatility, and dependence on successful clinical trials could pressure revenue if outcomes disappoint.